CJC-1295 and Ipamorelin Safety Questions: What Studies Report

Searches about CJC-1295 and ipamorelin frequently focus on safety: blood pressure, blood sugar, the heart, the pituitary, fertility, and whether long-term human data exist. This page summarises what the published literature actually reports, organised by study, model, dose and duration, and states plainly where no human data were located. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question, medication or peptide.

What the two compounds are, in the literature

CJC-1295 has been described in the published record as a long-acting analog of growth hormone-releasing hormone (GHRH) that acts on the pituitary to increase growth hormone (GH) and, downstream, insulin-like growth factor I (IGF-I). Researchers characterised this in healthy adults in a 2006 trial in The Journal of Clinical Endocrinology and Metabolism (PMID 16352683). Ipamorelin is described in animal work as a growth hormone secretagogue receptor 1a (ghrelin receptor) agonist — a ghrelin mimetic — for example in ferret studies of cisplatin-induced weight loss (PMID 39043357) and in a rodent postoperative ileus model (PMID 27186127).

Neither compound appears in the located literature as an approved drug product for general clinical use, and the two have not been studied together in any published human trial that could be identified among these papers.

Human tolerability data for CJC-1295: What Studies Report

The 2006 trial in healthy adults administered single subcutaneous doses of CJC-1295 at 30, 60 and 125 µg/kg, and multiple doses at 60 µg/kg or 90 µg/kg, and reported mean GH concentrations increased 2- to 10-fold for six days or more and IGF-I increased 1.5- to 3-fold for 9 to 11 days after a single injection (PMID 16352683). The study reported an estimated half-life of 5.8 to 8.1 days and described the analog as well tolerated, with no serious adverse reactions described in the trial report (PMID 16352683).

A related 2009 analysis in Growth Hormone & IGF Research examined serum from normal adult subjects after activation of the GH/IGF-1 axis by CJC-1295 and reported measurable changes in the serum protein profile associated with that activation (PMID 19386527). The researchers framed those protein changes as markers of axis activation rather than as clinical adverse events; the paper did not report cardiovascular outcomes.

Two points follow from the published record as it stands. First, the human tolerability evidence for CJC-1295 comes from short-duration studies in healthy adults, not from long-term use in mixed populations. Second, there is no located human safety trial for ipamorelin at all in this evidence set — the ipamorelin literature summarised below is animal work.

Blood pressure questions: What Studies Report

This is one of the most common search questions, and the honest answer from the located literature is that no identified study reported blood pressure as an outcome for CJC-1295, for ipamorelin, or for the two combined. The human CJC-1295 trial reported GH and IGF-I concentrations, pharmacokinetics and overall tolerability (PMID 16352683), and the follow-up analysis reported serum protein profile changes (PMID 19386527). Neither report, within its published scope, presented systolic or diastolic blood pressure data, heart rate data, or echocardiographic findings.

The animal ipamorelin literature located here examined insulin release (PMID 15665799), bone (PMID 10828840), gastric motility (PMID 27186127) and body weight during chemotherapy (PMID 39043357) — none reported blood pressure endpoints. Statements circulating online that either compound raises or lowers blood pressure are therefore not traceable to these published studies. Where a question has not been studied, the accurate description is "not measured," not "safe" and not "unsafe."

Glucose and insulin: What Studies Report

The most directly relevant metabolic paper is a 2004 study in Neuroendocrinology Letters that examined the mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats (PMID 15665799). The researchers reported that ipamorelin evoked insulin release in the isolated rat pancreas and investigated the signalling mechanism behind that release, in both normal and diabetic animals.

That finding is mechanistic and species-specific. It was reported in rat pancreatic tissue, not in humans, and the study did not report blood glucose outcomes in people. Growth hormone axis activation is widely discussed in endocrinology in relation to insulin sensitivity, but among the papers verified for this page, the only glucose-relevant experimental report is the rat pancreas study above. No human study located here reported fasting glucose, HbA1c or insulin sensitivity outcomes for CJC-1295 or ipamorelin.

Bone findings in animals: What Studies Report

Two rat studies examined skeletal endpoints. A 2000 paper in The Journal of Endocrinology reported that the GH secretagogues ipamorelin and GH-releasing peptide-6 increased bone mineral content in adult female rats (PMID 10828840). A 2001 paper in Growth Hormone & IGF Research reported that ipamorelin counteracted a glucocorticoid-induced decrease in bone formation in adult rats (PMID 11735244).

These were efficacy-oriented experiments in rodents rather than safety trials, and the effects they reported were on bone mineral content and bone formation markers in animals. They do not establish comparable outcomes in humans, and neither paper reported fracture outcomes or long-term skeletal safety in people.

Gastrointestinal and appetite-related findings: What Studies Report

Because ipamorelin acts at the ghrelin receptor, several papers examined gut and appetite endpoints. A rodent study of postoperative ileus reported that ipamorelin improved gastric dysmotility in that model (PMID 27186127). A 2024 ferret study reported that the growth hormone secretagogue receptor 1a agonists anamorelin and ipamorelin inhibited cisplatin-induced weight loss, and that anamorelin — but not ipamorelin in the same comparison — also exhibited anti-emetic effects via a central mechanism (PMID 39043357).

The ferret study is notable for a safety-adjacent reason: it distinguished between two agonists at the same receptor, with the researchers reporting that the anti-emetic effect was attributable to anamorelin acting centrally. That kind of compound-level difference is a reminder that effects reported for one ghrelin receptor agonist do not automatically transfer to another.

Reproductive and endocrine axis findings: What Studies Report

A 2024 paper in Animal Reproduction Science examined the influence of ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus (PMID 38996787). The study reported effects of ipamorelin on that reproductive axis in the fish model.

This is the only located study in this set that addressed reproductive axis endpoints for either compound, and it was conducted in fish. No human study located here reported testosterone, LH, FSH, menstrual or fertility outcomes for CJC-1295 or ipamorelin.

Product identity and unregulated supply: What Studies Report

Separate from physiological effects, the analytical literature documents identification problems. A 2010 report in Drug Testing and Analysis described the identification of CJC-1295 in an unknown pharmaceutical preparation, meaning the substance was characterised in a product whose contents were not otherwise declared (PMID 21204297). Two further papers described analytical methods developed for anti-doping purposes: an LC-MS/MS method for confirming CJC-1295 abuse in equine plasma (PMID 30938069) and an immuno-PCR screen for detecting CJC-1295 and other GHRH analogs in equine plasma (PMID 30489688).

These papers do not report human adverse events. They are cited here because the literature itself treats CJC-1295 as a substance encountered in unregulated preparations and in doping-control contexts — a setting in which identity, purity and concentration were not established by the analytical authors in advance.

Self-reported use outside clinical settings: What Studies Report

A 2016 netnographic study in Substance Use & Misuse examined online discussion by women about synthetic growth hormone-related use of CJC-1295, analysing forum content rather than clinical measurements (PMID 26771670). The researchers described how users discussed the substance within online communities.

Qualitative internet research of this kind documents what people said, not what happened physiologically. It carries no laboratory verification, no product testing and no clinical follow-up, so it cannot be read as an adverse-event dataset.

Summary table of located evidence

Where no data exist

• Combination studies: no located published trial administered CJC-1295 and ipamorelin together in humans or animals.
• Blood pressure and cardiac endpoints: not reported in any located study of either compound.
• Long-term human safety: the human CJC-1295 reports covered short study periods in healthy adults (PMID 16352683, PMID 19386527).
• Special populations: no located human data in pregnancy, in children, in people with cancer histories, or in people with diabetes for either compound.
• Human ipamorelin outcomes: the ipamorelin evidence located here was in rats, ferrets and fish only.

Again, this page is for educational purposes only and is not medical advice; consult a licensed physician about any personal health decision. Nothing here describes a protocol, and the doses named above are reported solely as the experimental conditions the cited investigators used.

References

• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults (The Journal of Clinical Endocrinology and Metabolism, 2006)
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (Growth Hormone & IGF Research, 2009)
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions (Substance Use & Misuse, 2016)
• The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus (Animal Reproduction Science, 2024)
• Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats (Neuroendocrinology Letters, 2004)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS (Drug Testing and Analysis, 2019)
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma (Drug Testing and Analysis, 2019)
• The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets (Physiology & Behavior, 2024)
• The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats (The Journal of Endocrinology, 2000)
• The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats (Growth Hormone & IGF Research, 2001)
• Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation (Drug Testing and Analysis, 2010)
• Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus (Journal of Experimental Pharmacology, 2012)